Immunis Inc., a clinical-stage biotechnology company, has closed a $25 million Series A-1 financing round to fund two Phase 2 clinical trials of its investigational therapy, IMM01-STEM. The funding round included follow-on investments from existing investors such as Remiges Ventures, Continuum Health Ventures, and BOLD Capital Partners, as well as new investments from LifeSpan Vision Ventures, JLS Fund, and a leading global insurance company.
IMM01-STEM is a stem cell-derived secretome product aimed at treating age-related muscle atrophy and metabolic dysfunction. The therapy demonstrated safety and tolerability in a Phase 1/2a clinical trial involving nine elderly patients, with no serious adverse events reported. Patients experienced improvements in quality-of-life measures related to physical function and pain, as well as a clinically relevant increase in gait speed.
Preclinical studies published in GeroScience and Aging Cell showed that IMM01-STEM reversed muscle atrophy, improved muscle function, enhanced metabolism, and decreased body and liver fat in aged mouse models. The upcoming Phase 2 trials will assess the therapy’s efficacy in elderly populations with sarcopenia, obesity, and metabolic dysfunction.
“”By running randomized, controlled studies in elderly populations with degenerative disease and metabolic dysfunction, we hope to demonstrate IMM01-STEM’s broad applicability in multiple medical conditions,”” said Mark Cabato, Chief Business Officer of Immunis.
